61
1
Monitor adherence and
response to therapy
1
Monitor adherence and
response to therapy
1
Monitor adherence and
response to therapy
Patient unable to tolerate,
obtain, or adhere to PCSK9
mAb therapy?
NO
YES
YES
≥50% LDL-C reduction,
LDL-C <55 mg/dL, and
non–HDL-C <85 mg/dL?
NO
YES
NO
1
Add ezetimibe and/or
PCSK9 mAb
2a
Initiate inclisiran* to
lower LDL-C
2a
Add bempedoic acid
>50% LDL-C reduction,
LDL-C <55 mg/dL,
non–HDL-C <85 mg/dL,
and apoB <55 mg/dL?
1
Monitor adherence and
response to therapy
